A midlife health guide includes low desire in a broader health conversation. Read the clinical context, evidence limits and practical meaning.
On October 21, 2026, Hackensack Meridian Health published “Women’s Health After 40: The New Rules for Healthy Aging.” Updated the following day, the guide includes low sex drive among symptoms worth discussing with a doctor when they are new, persistent, worsening or disruptive.
Its significance for sexual wellbeing is the setting: low desire appears within a wider account of midlife health rather than as an isolated problem. The update makes room for a sexual-health conversation without deciding what a change in desire means for an individual woman.
The article draws on advice from OB-GYN Kanchi Chadha and primary care physician Armida Priftani. Hackensack Meridian Health identifies both as leaders of its Women’s Midlife Health and Longevity Program.
The guide covers several areas of women’s health after 40:
This scope matters when interpreting the advice about low desire. The article is an overview of midlife health rather than a focused sexual-medicine guideline. Its purpose is to bring related health questions into view, not to supply a detailed assessment for every symptom it mentions.
Readers therefore encounter sexual wellbeing alongside preventive care and everyday health concerns. That placement gives desire a legitimate place in a general health discussion without making it the defining feature of midlife.
For readers interested in the longer view, Sexential’s coverage of sexual wellbeing beyond the menopause transition provides a related educational starting point. The news here is narrower: this particular guide explicitly includes low sex drive in its account of symptoms women may bring to a doctor.
Hackensack Meridian Health lists low sex drive alongside irregular periods, hot flashes and brain fog. Its prompt for medical discussion depends on the character of the symptom: whether it is new or continuing, getting worse or disrupting life.
That framing is useful because it begins with a woman’s experience rather than a presumed explanation. A reader can describe what has changed before knowing which area of care might be relevant. The guide makes mentioning a sexual concern part of the broader conversation about health.
The article also presents care coordination as an important part of the health system’s approach. Dr. Chadha describes a situation in which patients may see multiple specialists and then be left to connect their symptoms themselves. Hackensack Meridian Health presents its program as a way to connect aspects of care.
For readers, the practical point is that sexual concerns need not be left outside a general health discussion. The guide treats them as information worth hearing alongside other symptoms. It does not require the reader to arrive with a ready-made account of how those symptoms fit together.
The main update is clinician-led education rather than experimental or observational research. It reports no enrolled sample or follow-up period. It supplies neither a prevalence estimate for low desire nor a measured treatment effect.
The guide also does not establish that low desire is inevitable after 40. It does not say that menopause explains every change or that every change requires treatment. Its broad title should not be mistaken for a diagnosis that applies to all women in the same age group.
The health system’s account of coordinated care is its stated rationale for its own program. That explanation is not independent evidence that the program improves health outcomes.
These boundaries define the update’s value. It is a prompt to bring relevant symptoms into a medical conversation, not a study showing why a particular woman’s desire has changed. Questions about an individual cause or treatment belong in qualified clinical care.
A Contemporary OB/GYN report adds an important distinction to the guide’s broad symptom discussion. Quoting Holly N. Thomas, the report explains that low libido alone does not establish hypoactive sexual desire disorder, or HSDD. Clinically significant distress is part of that distinction.
The report also describes a biopsychosocial evaluation. In plain language, that means considering several domains rather than assuming one explanation:
This complements the health guide’s wider perspective. Hackensack Meridian Health makes space for the concern within midlife care. The clinical report explains why assessing that concern involves more than identifying a low level of desire.
Distress is therefore relevant information for an assessment, not a label readers need to assign themselves. The distinction also avoids treating all experiences of low desire as interchangeable. A description of desire and an account of what troubles someone about it are related but different parts of the conversation.
Sexential’s guide to the overlap between mental health and sexual wellbeing offers related context for this broader view. Including psychological questions does not remove the medical ones; the clinical report places them within the same assessment.
The guide’s broader health framing should also be kept separate from claims about a particular treatment. A Menopause Society press release describing research presented at its 2026 annual meeting illustrates why that distinction matters.
The release described a retrospective study using the TriNetX US Collaborative Network. It included more than 6,300 propensity-matched menopausal women. The researchers reported composite cardiovascular outcomes in 3.8% of the testosterone-exposed group and 0.5% of the comparison group.
Those findings describe an association, not proof that testosterone caused the outcomes. The Society said absolute event rates were low and long-term safety data remain limited. It called for further prospective investigation.
The same release says testosterone has evidence of effectiveness for HSDD. It describes insufficient evidence for using it to manage fatigue or memory loss, weight gain or bone-density loss. It also notes that no testosterone product is FDA-approved for women in the United States and that prescribing it to women is off-label.
This is a separate evidence question from whether a woman should mention changing desire. The clinical discussion comes first; a treatment mentioned in coverage of menopause is not automatically the answer to a symptom. Individual risk-benefit decisions require qualified care.
For readers, the useful takeaway is not a new rule about how much desire someone should have after 40. It is a clearer way to describe a concern without first deciding its cause or giving it a diagnostic name.
The sources support several topics for that conversation:
These are topics for discussion rather than a self-assessment checklist. They do not require a reader to sort every concern into a hormonal or nonhormonal category before speaking. The guide’s coordination argument is relevant here: bringing information together is different from expecting a patient to explain every connection.
For someone uncertain how to put an experience into words, language for describing changes in sexual function can provide additional educational context. A medical conversation can begin with a description rather than a conclusion.
The quieter significance of this update is where it places desire. Not outside general health and not at the centre of every midlife change, but among the experiences a woman can describe and have taken seriously.
Reading low desire as evidence of personal failure can add anxiety to an already uncertain change. Sexential counters that framing with calm sexual wellbeing education for adults aged 35 to 65, placing confidence and intimacy alongside biological context while keeping its role educational rather than diagnostic or prescriptive.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A report on a student survey links attention with men’s sexual satisfaction. Here’s the evidence, its limits and the practical context for midlife.
A new report puts men’s midlife testosterone changes in context, with guidance on assessment, partner conversations and fertility considerations.
The Menopause Society’s 2026 program places lifestyle, sleep and sexual health together. Here is what the agenda and partner research actually report.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
